We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Karo Bio Announces that Merck & Co. Plans to Proceed With Phase II Clinical Evaluation of Candidate Compound

News   Nov 27, 2009

 
Karo Bio Announces that Merck & Co. Plans to Proceed With Phase II Clinical Evaluation of Candidate Compound
 
 
 

RELATED ARTICLES

Team Redesign Molecules To Fight Malaria

News

Redesigning molecules originally developed to treat the skin disease psoriasis could lead to an effective new drug against malaria, according to new study findings.

READ MORE

Evidence Reinforcing Approval of New Cancer Drugs Raises Questions

News

Around half of trials that supported new cancer drug approvals in Europe between 2014 and 2016 were judged to be at high risk of bias, according to a new study.

READ MORE

Treating Blood Cancers With a Low-cost Arthritis Drug

News

A simple arthritis drug could be an effective, low-cost solution to treat patients with blood cancers, according to a new study by the University of Sheffield.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE